In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cyclacel's Mechanistic Approach to R&D

Executive Summary

Cyclacel does not have a late-stage or marketed product. But a singular focus on the biology of the cell cycle, a strong early-stage pipeline and a set of broadly applicable biomarker technologies that may minimize development risk has kept investors interested. Cyclacel has been able to complement its internal pipeline with two recent in-licensing deals, and as capital cautiously returns to European biotech, the company expects to leverage its approach to build value not only in cancer but in other proliferative diseases as well.
Advertisement

Related Content

More Funding Options for European biotech
Roche's Challenging Biomarker Strategy
Getting Late Stage Products Early

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004833

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel